Matthew Helmin-Walker

Global Scientific Relations MASH/Obesity. Passionate about academic expert and patient perspectives. Views expressed are my own.

[Steven Kahn @StevenKahn11]

I grew up in apartheid S Africa, where muzzling of speech and encroachment on academic freedom were the norm. I came to the US to pursue a career in science. I never thought that at this stage of my career, I would ever experience my youth again. #StandUpForScience #ADA #ADA2026

[Scott Isaacs @scottisaacsmd]

The genetics of obesity: This new @NatMetabolism review shows obesity is highly heritable, with more than 85 monogenic forms and over 1,000 GWAS loci, and is rapidly opening the door to true precision medicine (MC4R agonists, PRSs, genotype-guided therapies) for our patients living with obesity.
https://t.co/zfSgCkwx5x

[Scott Isaacs @scottisaacsmd]

The new @TheAACE diabetes algorithm with its complications-centric approach to T2D care that prioritizes HF, CKD, ASCVD, stroke or TIA, and now #MASLD for the first time represents a major advance in clinical practice. I am proud that AACE is leading by formally integrating MASLD into diabetes treatment decisions.
https://t.co/RJm4uwAZYu

[Scott Isaacs @scottisaacsmd]

Reduced-frequency GLP-1 as a maintenance strategy: in this case series, patients who tapered from weekly semaglutide/tirzepatide to less frequent dosing maintained weight loss, body composition, and metabolic syndrome gains, supporting structured de-escalation to lower burden without sacrificing efficacy.
https://t.co/xfKxfOb858

[JAMA @JAMA_current]

Meta-analysis: #SGLT2 inhibitors slow kidney decline consistently across CKD severity and albuminuria range, supporting their routine use for kidney health. 🧵

#KidneyWK @ASNKidney

https://t.co/ejNvhAl5IE

[Matthew Helmin-Walker @HelminWalker]

@KevinH_PhD Thanks for all that you’ve done to advance our understanding of the food environment.

[Matthew Helmin-Walker @HelminWalker]

@nasreenalfaris @ObesitySociety @IfsoSecretariat @ASMBSIH @KFMC_RIYADH Wonderful presentation thoroughly exploring the current AOM landscape from @nasreenalfaris

[Scott Isaacs @scottisaacsmd]

New nomenclature for steatotic liver disease proposes a new category, termed #MetALD to designate those with #MASLD who consume moderate amounts of alcohol (140–350 g per week for men and 210–420 g per week for women).
https://t.co/t15T5xHfP9

[Matthew Helmin-Walker @HelminWalker]

https://t.co/OQRTvVJvFb

[Scott Isaacs @scottisaacsmd]

Number 3 Top Cardiometabolic Story of 2023:
The SELECT trial, published in November showed that #semaglutide reduced the risk of cardiovascular death by 20% in patients with obesity without diabetes.
https://t.co/TZePPbQw5F

[Rohit Loomba @DrLoomba]

Renamed, common liver diseases might get fairer shake at treatment, researchers hope https://t.co/HAVp2arAkJ via @statnews

[Matthew Helmin-Walker @HelminWalker]

@Drlipid @ErinMichos Love Dr. Michos… such a brilliant and genuine person!

[Scott Isaacs @scottisaacsmd]

Outstanding "Primary Care Hack" on the identification and management of people with NAFLD/MASLD and NASH/MASH. https://t.co/06MaHvvMxy

[EASO @EASOobesity]

The International Obesity Committee has recently developed statements on BMI and Weight loss vs Obesity Management.

Read both statements here: https://t.co/mpt3qWpgO2

@ObesityAction @ASMBS @eatright @GOPAObesity
@ObesityCan @OMAsocial @STOPObesity @ObesitySociety
@STOPObesity

[Ted Kyle @ConscienHealth]

Tomorrow from 9 am to Noon, join me and a host of brilliant people sharing insights on ethics, equity, and stigma in obesity treatment and policy. The full agenda is here: https://t.co/uKlrCaQU1H

Register for free here: https://t.co/54mOI7AJw7

[Matthew Helmin-Walker @HelminWalker]

@PaulJellinger discussing the role of lipids in treating CRM conditions at #WCIRDC2023 in Los Angeles

[Matthew Helmin-Walker @HelminWalker]

Wonderful long week in Dallas for the SYNCHRONIZE investigator meeting & @ObesityWeek . Great to see @AniaJastreboff @TonyComuzzie @IldikoLingvay @JaimeAlmandoz @askdrfatima @AaronKelly_PhD @seanwharton @ConscienHealth @drard Ian Neeland Lee Kaplan Leigh Perrault @ObesitySociety

[Matthew Helmin-Walker @HelminWalker]

Role of SGLT2i in HF - ESC2023

Wonderful job, @ShelleyZieroth @JavedButler1 @mrchrtfaildoc @TheresaMcDonag3 Stefan Anker!

[Muhammad Shariq Usman @ShariqUsmanMD]

In the EMPEROR trials, physiologic benefits of Empa quickly dissipated after blinded withdrawal of trial therapy.

Read our paper @CircAHA https://t.co/u4lmRIOBOn

TL;DR: Benefits of SGLT2i persist after years and tx should be maintained!

@JavedButler1 @UTSWNews @UTSWIMchief

[Andrew J Sauer MD @AndrewJSauer]

An historic Class 1A recommendation for HFpEF. Expected but still remarkable. #ESCCongress

@escardio

Proud of the many who brought this forward for our patients.

@MkosiborodMD
@MidAmericaHeart
@saintlukeskc